A study on 172 live patients receiving hemodialysis indicated that higher age is one of the factors that reduce the effectiveness of hepatitis B vaccine in hemodialysis patients. 
Introduction
Hemodialysis patients are at higher risks of infection with hepatitis B virus compared to normal people (1) . To prevent the spread of this infection in hemodialysis patients, the administration of hepatitis B vaccine has been recommended. However, the response to the vaccine in these patients has been reported to be lower than healthy people (2) . In patients with advanced renal failure, there is a suppression of immune system due to uremia which results in a decrease in their response to the vaccine (3). Various factors have been found to affect the level of response to vaccines such as age, gender, nutritional status, the duration of dialysis, history of diabetes, dry weight, and hepatitis C antibody (4) .
Patients with renal failure who have not yet reached the dialysis stage respond better to hepatitis B vaccination which shows the relationship between immune response and the level of renal failure (5) . Various strategies have been proposed to increase the immune response to the vaccine in these patients. Among them are the addition of one extra dose of vaccination (4 doses) or doubling the dose of the vaccine (40 µg). The employment of these methods has caused the level of seroconversion in patients to reach even 80% after taking the vaccine (6). However, there are paradoxes in different studies. That is why in this study we aimed to investigate the efficacy of double dose hepatitis B vaccination and the factors affecting the response to it in hemodialysis patients in Ardabil, Iran.
Objectives
The present study aimed to determine the level of response to hepatitis B vaccination in patients under hemodialysis.
Patients and methods

Study population
This study was conducted on all of the patients who were receiving hemodialysis maintenance since March 2015 in the dialysis department of Buali hospital in Ardabil. The effect of vaccination on them was investigated with reference to their records where in their antibody levels were recorded. Before dialysis, antibodies against hepatitis B and C were checked in all of the patients. Those for whom HBsAg and HBsAb results were negative and had not received the vaccine for hepatitis B in the past entered to the study. To collect information about the patients, a checklist was prepared and the information such as name, surname, age, gender, and diabetes history, serological profiles of hepatitis B, C and also body mass index (BMI) were recorded. A double dose of hepatitis B vaccine was administered to the patients in a 3-dose schedule at 0, 1 and 6 months after the beginning of dialysis. The response to the vaccine was investigated by measuring the patients' level of hepatitis B antibody one month after receiving the last dose of the vaccine. According to their HBsAb antibody level, the patients were divided into three groups as follows; 1. Patients without response (whose antibody levels were lower than 10 mIU/mL) 2. Patients with poor response (whose antibody levels were in the range of 10-100 mIU/mL) 3. Patients with proper response (whose antibody levels were higher than 100 mIU/mL). The antibody levels of each patient were recorded in their own checklist. Then, at the end of the study, the changes in serum HBsAb levels and their relationship with demographic factors were investigated. Patients who were receiving chemotherapy or consuming immunosuppressive drugs were excluded from the study.
Ethical considerations
This study was conducted following the Declaration of Helsinki principles. Informed written consent was obtained from each hemodialysis patient. The protocol of this study was approved by the Medical Ethics Committee of Ardabil University of Medical Sciences with the reference code of IR.ARUMS.REC.1394.62.
Statistical analysis
After collecting the data, they were coded and fed into SPSS Software version 19. Data analyzed using the inferential statistics of chi-square test, t test, and Pearson's correlation test and reported in figures and tables using the descriptive statistical methods. In all instances, the significance level was set at 0.05.
Results
In this study, 181 hemodialysis patients were selected to be studied. Nine of them were excluded because of receiving chemotherapy or consuming immunosuppressive drugs. As a result, 172 patients remained of whom 98 were male and 74 were female. The mean age of the remaining patients was 61.19 ± 15.47 years and most of them (45 patients constituting 26.2% of the total patients) were in the age range of 60-70 years. In this study, antibody against hepatitis C was not observed in the patients. The statistical analysis of antibody titers against hepatitis B one month after the injection of the last dose of the vaccine indicated that 34 patients (19.8%) have titers lower than 10 mIU/mL, 68 patients (39.5%) have titers in the range of 10-100 mIU/mL, and 70 patients (40.7%) have titers higher than 100 mIU/mL (Figure 1 ). Antibody titers were 25.62±4.74 in males and 26.41±3.89 in females, with no significant difference between two genders (P = 0.40). On the other hand, the results of Pearson's correlation test indicated a negative correlation between patients' age and the level of titer induced by vaccination (P = 0.001, r = -0.37). The negative value of correlation coefficient shows 10-100 >100 (Table 2) .
Discussion
The results of the present study revealed no significant relationship exists between the patients' gender and the level of antibody titers induced as the result of hepatitis B vaccine. Similar to our finding, Navarro et al (4) also did not observe a significant relationship between the levels of immune titers in male and female hemodialysis patients after the injection of hepatitis B vaccine. In some studies, the response to the vaccine has been found to be higher in females compared to male patients and the concentration of anti-HBs antibody produced in females has been reported to be three times as much as that produced in males (7). Pasco et al (8) investigated 111 hemodialysis patients. They observed a significant difference between males and females in their level of vaccination-induced immunity where the level of immunity in females was higher than that of males. However, it is not clearly known whether this difference in response is due to the difference in the body weight of the two genders or their sex hormones. In one study, this difference between males and females has been attributed to their body weight and it has been observed that when it is taken care of, the difference between the two groups in their response to vaccination no longer exists (9) . Our analysis in this study indicated that the effectiveness of vaccination significantly decreases as the age increases and older patients show lower response to the vaccine. In line with our finding, some studies have reported that patients under 40 years of age respond better to vaccination than those who are over that age (9) . Similarly, Navarro et al (4) in their study revealed that as the age increases, the level of vaccination-induced immunity against hepatitis B in hemodialysis patients decreases. Peces et al (10) injected 40 µg of the vaccine to patients in a 4-dose schedule. They observed proper response in 77.5% of the patients 72.5% of whom had given a high immune response to the vaccination. They reported high response to vaccination in 100% of the patients under 40 and 74% of the patients over 60 years old. In their follow-up of hemodialysis patients, Buti et al (11) observed that 41% of the patients lost their anti-HBs after 3 years. Those who had preserved their anti-HBs were younger and had higher levels of anti-HBs (11). This might be related to the decrease in immune system strength as the age increase which leads to a poor response to vaccination. According to the findings of the present study, higher age is one of the factors that affect HBsAb titer. It decreases the efficacy of hepatitis B vaccine which might be the result of the changes in the immune system of the body as people age (12) . According to the findings of the studies conducted by Pasco et al (8), Elwell et al (13), Katedra et al (14) and Ebrahim et al (15) , no significant relationship was observed between the patients' age, gender, and HCV infection and the efficacy of hepatitis B vaccination for them. Moreover (17) and Ebrahim et al (15) did not find BMI of hemodialysis patients to be an effective factor in their response to hepatitis B vaccine. This lack of correlation can be attributed to the dependence of response to vaccination to multiple factors. In their study, Al Saran et al (12) found that gaining weight is a negative factor affecting the level of immunity induced as the result of hepatitis B vaccination in hemodialysis patients. Our findings indicated that smoking and the vaccinationinduced immunity are not significantly related to each other. In line with our finding, no significant relationship was found between smoking and the level of vaccinationinduced immunity in the study by Al Saran et al (12) . A possible reason for this finding might be the limited number of smokers included in this study. In some studies, whose findings are inconsistent with ours, a decrease has been reported in smokers' anti-HBs response after getting vaccinated with hepatitis B vaccine (18, 20) . The probable mechanism for this result might be the effect of smoking on the reduction of immune response which, in turn, leads to a lower response to the vaccine. In another study, Fabrizi et al (22) found that the level of immunity induced as the result of hepatitis B vaccination is lower in hemodialysis patients suffering from diabetes compared to those without diabetes. Some of the factors that have been found to cause this difference are defective cellular immunity in diabetic patients (23) , the reduction of B-lymphocyte cells and CD4/CD8 ratio of lymphocytes (24) , and the impaired synthesis of antigens (25) . In all, the findings of our study indicated that in hemodialysis patients, gender, BMI, smoking, and having diabetes do not correlate significantly with the response to hepatitis B vaccine, while higher age significantly decreases its effectiveness.
Conclusion
Higher age was found to be one of the risk factors that decrease the efficacy of hepatitis B vaccination in hemodialysis patients. Therefore, it is recommended that in patients with this risk factor more care be taken and more careful follow-ups be conducted over time.
Limitations of the study
The small proportion of patients included in this study was one the limitations of this research.
